Sichenzia Ross Ference LLP Represents INmune Bio Inc. in an $8 Million Initial Public Offering and Listing on the Nasdaq Capital Market
Press Release – New York, NY – February 5, 2019 – Sichenzia Ross Ference (“SRF”), a leading securities and corporate law firm, is pleased to announce that the firm has represented INmune Bio Inc. (INMB), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, in an initial public offering at a price of $8.00 per share resulting in gross proceeds of approximately $8,000,000 and listing on the Nasdaq Capital Market under the ticker symbol INMB.
The SRF team was led by Partners Marc Ross, Thomas Rose and David Manno. View more of Sichenzia Ross Ference’s IPO transactions, here.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019